Gut Microbiome: Profound Implications for Diet and Disease

Ronald D Hills Jr, Benjamin A Pontefract, Hillary R Mishcon, Cody A Black, Steven C Sutton, Cory R Theberge, Ronald D Hills Jr, Benjamin A Pontefract, Hillary R Mishcon, Cody A Black, Steven C Sutton, Cory R Theberge

Abstract

The gut microbiome plays an important role in human health and influences the development of chronic diseases ranging from metabolic disease to gastrointestinal disorders and colorectal cancer. Of increasing prevalence in Western societies, these conditions carry a high burden of care. Dietary patterns and environmental factors have a profound effect on shaping gut microbiota in real time. Diverse populations of intestinal bacteria mediate their beneficial effects through the fermentation of dietary fiber to produce short-chain fatty acids, endogenous signals with important roles in lipid homeostasis and reducing inflammation. Recent progress shows that an individual's starting microbial profile is a key determinant in predicting their response to intervention with live probiotics. The gut microbiota is complex and challenging to characterize. Enterotypes have been proposed using metrics such as alpha species diversity, the ratio of Firmicutes to Bacteroidetes phyla, and the relative abundance of beneficial genera (e.g., Bifidobacterium, Akkermansia) versus facultative anaerobes (E. coli), pro-inflammatory Ruminococcus, or nonbacterial microbes. Microbiota composition and relative populations of bacterial species are linked to physiologic health along different axes. We review the role of diet quality, carbohydrate intake, fermentable FODMAPs, and prebiotic fiber in maintaining healthy gut flora. The implications are discussed for various conditions including obesity, diabetes, irritable bowel syndrome, inflammatory bowel disease, depression, and cardiovascular disease.

Keywords: Western diet; cardiometabolic risk factors; chronic health conditions; gastrointestinal disorders; gut microbiota; habitual diets; nutrition; obesity; prebiotics and probiotics.

Conflict of interest statement

C.R.T. has an ownership stake in Noble Wellness, LLC. S.C.S. is the founder of Simulation Consultation Services. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

    1. Conlon M.A., Bird A.R. The impact of diet and lifestyle on gut microbiota and human health. Nutrients. 2015;7:17–44. doi: 10.3390/nu7010017.
    1. Singh R.K., Chang H.W., Yan D., Lee K.M., Ucmak D., Wong K., Abrouk M., Farahnik B., Nakamura M., Zhu T.H., et al. Influence of diet on the gut microbiome and implications for human health. J. Transl. Med. 2017;15:73. doi: 10.1186/s12967-017-1175-y.
    1. Brennan C.A., Garrett W.S. Gut microbiota, inflammation, and colorectal cancer. Annu. Rev. Microbiol. 2016;70:395–411. doi: 10.1146/annurev-micro-102215-095513.
    1. Valdes A.M., Walter J., Segal E., Spector T.D. Role of the gut microbiota in nutrition and health. BMJ. 2018;361:k2179. doi: 10.1136/bmj.k2179.
    1. Qin J., Li R., Raes J., Arumugam M., Burgdorf K.S., Manichanh C., Nielsen T., Pons N., Levenez F., Yamada T., et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464:59–65. doi: 10.1038/nature08821.
    1. Almeida A., Mitchell A.L., Boland M., Forster S.C., Gloor G.B., Tarkowska A., Lawley T.D., Finn R.D. A new genomic blueprint of the human gut microbiota. Nature. 2019;568:499–504. doi: 10.1038/s41586-019-0965-1.
    1. Rothschild D., Weissbrod O., Barkan E., Kurilshikov A., Korem T., Zeevi D., Costea P.I., Godneva A., Kalka I.N., Bar N., et al. Environment dominates over host genetics in shaping human gut microbiota. Nature. 2018;555:210–215. doi: 10.1038/nature25973.
    1. Noble R.E. Waist-to-hip ratio versus BMI as predictors of cardiac risk in obese adult women. West. J. Med. 2001;174:240–241. doi: 10.1136/ewjm.174.4.240-a.
    1. Hamer M., O’Donovan G., Stensel D., Stamatakis E. Normal-Weight central obesity and risk for mortality. Ann. Intern. Med. 2017;166:917–918. doi: 10.7326/L17-0022.
    1. Gentile C.L., Weir T.L. The gut microbiota at the intersection of diet and human health. Science. 2018;362:776–780. doi: 10.1126/science.aau5812.
    1. Lauderdale D.S., Rathouz P.J. Body mass index in a US national sample of Asian Americans: Effects of nativity, years since immigration and socioeconomic status. Int. J. Obes. 2000;24:1188–1194. doi: 10.1038/sj.ijo.0801365.
    1. Vangay P., Johnson A.J., Ward T.L., Al-Ghalith G.A., Shields-Cutler R.R., Hillmann B.M., Lucas S.K., Beura L.K., Thompson E.A., Till L.M., et al. US immigration westernizes the human gut microbiome. Cell. 2018;175:962–972. doi: 10.1016/j.cell.2018.10.029.
    1. Arumugam M., Raes J., Pelletier E., Le Paslier D., Yamada T., Mende D.R., Fernandes G.R., Tap J., Bruls T., Batto J.M., et al. Enterotypes of the human gut microbiome. Nature. 2011;473:174–180. doi: 10.1038/nature09944.
    1. Wu G.D., Chen J., Hoffmann C., Bittinger K., Chen Y.Y., Keilbaugh S.A., Bewtra M., Knights D., Walters W.A., Knight R., et al. Linking long-term dietary patterns with gut microbial enterotypes. Science. 2011;334:105–108. doi: 10.1126/science.1208344.
    1. Rajilic-Stojanovic M., Jonkers D.M., Salonen A., Hanevik K., Raes J., Jalanka J., De Vos W.M., Manichanh C., Golic N., Enck P., et al. Intestinal microbiota and diet in IBS: Causes, consequences, or epiphenomena? Am. J. Gastroenterol. 2015;110:278–287. doi: 10.1038/ajg.2014.427.
    1. Hall A.B., Yassour M., Sauk J., Garner A., Jiang X., Arthur T., Lagoudas G.K., Vatanen T., Fornelos N., Wilson R., et al. A novel Ruminococcus gnavus clade enriched in inflammatory bowel disease patients. Genome Med. 2017;9:103. doi: 10.1186/s13073-017-0490-5.
    1. Henke M.T., Kenny D.J., Cassilly C.D., Vlamakis H., Xavier R.J., Clardy J. Ruminococcus gnavus, a member of the human gut microbiome associated with Crohn’s disease, produces an inflammatory polysaccharide. Proc. Natl. Acad. Sci. USA. 2019;116:12672–12677. doi: 10.1073/pnas.1904099116.
    1. Kim E.R., Chang D.K. Colorectal cancer in inflammatory bowel disease: The risk, pathogenesis, prevention and diagnosis. World J. Gastroenterol. 2014;20:9872–9881. doi: 10.3748/wjg.v20.i29.9872.
    1. Jandhyala S.M., Talukdar R., Subramanyam C., Vuyyuru H., Sasikala M., Nageshwar Reddy D. Role of the normal gut microbiota. World J. Gastroenterol. 2015;21:8787–8803. doi: 10.3748/wjg.v21.i29.8787.
    1. Winter S.E., Baumler A.J. Dysbiosis in the inflamed intestine: Chance favors the prepared microbe. Gut Microbes. 2014;5:71–73. doi: 10.4161/gmic.27129.
    1. Martinez-Medina M., Garcia-Gil L.J. Escherichia coli in chronic inflammatory bowel diseases: An update on adherent invasive Escherichia coli pathogenicity. World J. Gastrointest. Pathophysiol. 2014;5:213–227. doi: 10.4291/wjgp.v5.i3.213.
    1. Lewis J.D., Chen E.Z., Baldassano R.N., Otley A.R., Griffiths A.M., Lee D., Bittinger K., Bailey A., Friedman E.S., Hoffmann C., et al. Inflammation, antibiotics, and diet as environmental stressors of the gut microbiome in pediatric Crohn’s disease. Cell Host Microbe. 2015;18:489–500. doi: 10.1016/j.chom.2015.09.008.
    1. Margolis D.J., Fanelli M., Hoffstad O., Lewis J.D. Potential association between the oral tetracycline class of antimicrobials used to treat acne and inflammatory bowel disease. Am. J. Gastroenterol. 2010;105:2610–2616. doi: 10.1038/ajg.2010.303.
    1. Lloyd D.A., Powell-Tuck J. Artificial nutrition: Principles and practice of enteral feeding. Clin. Colon Rectal Surg. 2004;17:107–118. doi: 10.1055/s-2004-828657.
    1. Llewellyn S.R., Britton G.J., Contijoch E.J., Vennaro O.H., Mortha A., Colombel J.F., Grinspan A., Clemente J.C., Merad M., Faith J.J. Interactions between diet and the intestinal microbiota alter intestinal permeability and colitis severity in mice. Gastroenterology. 2018;154:1037–1046. doi: 10.1053/j.gastro.2017.11.030.
    1. Chiba M., Abe T., Tsuda H., Sugawara T., Tsuda S., Tozawa H., Fujiwara K., Imai H. Lifestyle-related disease in Crohn’s disease: Relapse prevention by a semi-vegetarian diet. World J. Gastroenterol. 2010;16:2484–2495. doi: 10.3748/wjg.v16.i20.2484.
    1. Lewis J.D., Abreu M.T. Diet as a trigger or therapy for inflammatory bowel diseases. Gastroenterology. 2017;152:398–414. doi: 10.1053/j.gastro.2016.10.019.
    1. Roy C.C., Kien C.L., Bouthillier L., Levy E. Short-chain fatty acids: Ready for prime time? Nutr. Clin. Pract. 2006;21:351–366. doi: 10.1177/0115426506021004351.
    1. Sims I.M., Ryan J.L., Kim S.H. In vitro fermentation of prebiotic oligosaccharides by Bifidobacterium lactis HN019 and Lactobacillus spp. Anaerobe. 2014;25:11–17. doi: 10.1016/j.anaerobe.2013.11.001.
    1. Andoh A. Physiological role of gut microbiota for maintaining human health. Digestion. 2016;93:176–181. doi: 10.1159/000444066.
    1. Ohira H., Tsutsui W., Fujioka Y. Are short chain fatty acids in gut microbiota defensive players for inflammation and atherosclerosis? J. Atheroscler. Thromb. 2017;24:660–672. doi: 10.5551/jat.RV17006.
    1. Sivaprakasam S., Prasad P.D., Singh N. Benefits of short-chain fatty acids and their receptors in inflammation and carcinogenesis. Pharmacol. Ther. 2016;164:144–151. doi: 10.1016/j.pharmthera.2016.04.007.
    1. Morrison D.J., Preston T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes. 2016;7:189–200. doi: 10.1080/19490976.2015.1134082.
    1. Bergman E.N. Energy contributions of volatile fatty acids from the gastrointestinal tract in various species. Physiol. Rev. 1990;70:567–590. doi: 10.1152/physrev.1990.70.2.567.
    1. Kim S., Kim J.H., Park B.O., Kwak Y.S. Perspectives on the therapeutic potential of short-chain fatty acid receptors. BMB Rep. 2014;47:173–178. doi: 10.5483/BMBRep.2014.47.3.272.
    1. Singh N., Gurav A., Sivaprakasam S., Brady E., Padia R., Shi H., Thangaraju M., Prasad P.D., Manicassamy S., Munn D.H., et al. Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. Immunity. 2014;40:128–139. doi: 10.1016/j.immuni.2013.12.007.
    1. Ang Z., Ding J.L. GPR41 and GPR43 in obesity and inflammation—Protective or causative? Front. Immunol. 2016;7:28. doi: 10.3389/fimmu.2016.00028.
    1. Litvak Y., Byndloss M.X., Baumler A.J. Colonocyte metabolism shapes the gut microbiota. Science. 2018;362:eaat9076. doi: 10.1126/science.aat9076.
    1. Romick-Rosendale L.E., Haslam D.B., Lane A., Denson L., Lake K., Wilkey A., Watanabe M., Bauer S., Litts B., Luebbering N., et al. Antibiotic exposure and reduced short chain fatty acid production after hematopoietic stem cell transplant. Biol. Blood Marrow Transpl. 2018;24:2418–2424. doi: 10.1016/j.bbmt.2018.07.030.
    1. Wassenaar T.M. Insights from 100 years of research with probiotic E. coli. Eur. J. Microbiol. Immunol. 2016;6:147–161. doi: 10.1556/1886.2016.00029.
    1. Byndloss M.X., Olsan E.E., Rivera-Chavez F., Tiffany C.R., Cevallos S.A., Lokken K.L., Torres T.P., Byndloss A.J., Faber F., Gao Y., et al. Microbiota-activated PPAR-gamma signaling inhibits dysbiotic Enterobacteriaceae expansion. Science. 2017;357:570–575. doi: 10.1126/science.aam9949.
    1. Winter S.E., Winter M.G., Xavier M.N., Thiennimitr P., Poon V., Keestra A.M., Laughlin R.C., Gomez G., Wu J., Lawhon S.D., et al. Host-derived nitrate boosts growth of E. coli in the inflamed gut. Science. 2013;339:708–711. doi: 10.1126/science.1232467.
    1. Xu J., Chen N., Wu Z., Song Y., Zhang Y., Wu N., Zhang F., Ren X., Liu Y. 5-Aminosalicylic acid alters the gut bacterial microbiota in patients with ulcerative colitis. Front. Microbiol. 2018;9:1274. doi: 10.3389/fmicb.2018.01274.
    1. Pang T., Leach S.T., Katz T., Day A.S., Ooi C.Y. Fecal biomarkers of intestinal health and disease in children. Front. Pediatr. 2014;2:6. doi: 10.3389/fped.2014.00006.
    1. Huda-Faujan N., Abdulamir A.S., Fatimah A.B., Anas O.M., Shuhaimi M., Yazid A.M., Loong Y.Y. The impact of the level of the intestinal short chain fatty acids in inflammatory bowel disease patients versus healthy subjects. Open Biochem. J. 2010;4:53–58. doi: 10.2174/1874091X01004010053.
    1. Granado-Serrano A.B., Martin-Gari M., Sanchez V., Riart Solans M., Berdun R., Ludwig I.A., Rubio L., Vilaprinyo E., Portero-Otin M., Serrano J.C.E. Faecal bacterial and short-chain fatty acids signature in hypercholesterolemia. Sci. Rep. 2019;9:1772. doi: 10.1038/s41598-019-38874-3.
    1. Imperiale T.F., Gruber R.N., Stump T.E., Emmett T.W., Monahan P.O. Performance characteristics of fecal immunochemical tests for colorectal cancer and advanced adenomatous polyps: A systematic review and meta-analysis. Ann. Intern. Med. 2019;170:319–329. doi: 10.7326/M18-2390.
    1. Lazaridis N., Germanidis G. Current insights into the innate immune system dysfunction in irritable bowel syndrome. Ann. Gastroenterol. 2018;31:171–187. doi: 10.20524/aog.2018.0229.
    1. Yao X., Yang Y.S., Cui L.H., Zhao K.B., Zhang Z.H., Peng L.H., Guo X., Sun G., Shang J., Wang W.F., et al. Subtypes of irritable bowel syndrome on Rome III criteria: A multicenter study. J. Gastroenterol. Hepatol. 2012;27:760–765. doi: 10.1111/j.1440-1746.2011.06930.x.
    1. Lacy B.E., Mearin F., Chang L., Chey W.D., Lembo A.J., Simren M., Spiller R. Bowel Disorders. Gastroenterology. 2016;150:1393–1407. doi: 10.1053/j.gastro.2016.02.031.
    1. Hughes P.A., Zola H., Penttila I.A., Blackshaw L.A., Andrews J.M., Krumbiegel D. Immune activation in irritable bowel syndrome: Can neuroimmune interactions explain symptoms? Am. J. Gastroenterol. 2013;108:1066–1074. doi: 10.1038/ajg.2013.120.
    1. Langhorst J., Junge A., Rueffer A., Wehkamp J., Foell D., Michalsen A., Musial F., Dobos G.J. Elevated human beta-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome. Am. J. Gastroenterol. 2009;104:404–410. doi: 10.1038/ajg.2008.86.
    1. Farup P.G., Rudi K., Hestad K. Faecal short-chain fatty acids - a diagnostic biomarker for irritable bowel syndrome? BMC Gastroenterol. 2016;16:51. doi: 10.1186/s12876-016-0446-z.
    1. Linsalata M., Riezzo G., D’Attoma B., Clemente C., Orlando A., Russo F. Noninvasive biomarkers of gut barrier function identify two subtypes of patients suffering from diarrhoea predominant-IBS: A case-control study. BMC Gastroenterol. 2018;18:167. doi: 10.1186/s12876-018-0888-6.
    1. Mu Q., Kirby J., Reilly C.M., Luo X.M. Leaky gut as a danger signal for autoimmune diseases. Front. Immunol. 2017;8:598. doi: 10.3389/fimmu.2017.00598.
    1. Briskey D., Heritage M., Jaskowski L.A., Peake J., Gobe G., Subramaniam V.N., Crawford D., Campbell C., Vitetta L. Probiotics modify tight-junction proteins in an animal model of nonalcoholic fatty liver disease. Ther. Adv. Gastroenterol. 2016;9:463–472. doi: 10.1177/1756283X16645055.
    1. Wang L., Fouts D.E., Starkel P., Hartmann P., Chen P., Llorente C., DePew J., Moncera K., Ho S.B., Brenner D.A., et al. Intestinal REG3 lectins protect against alcoholic steatohepatitis by reducing mucosa-associated microbiota and preventing bacterial translocation. Cell Host Microbe. 2016;19:227–239. doi: 10.1016/j.chom.2016.01.003.
    1. Carabotti M., Scirocco A., Maselli M.A., Severi C. The gut-brain axis: Interactions between enteric microbiota, central and enteric nervous systems. Ann. Gastroenterol. 2015;28:203–209.
    1. Quigley E.M.M. The gut-brain axis and the microbiome: Clues to pathophysiology and opportunities for novel management strategies in irritable bowel syndrome (IBS) J. Clin. Med. 2018;7:6. doi: 10.3390/jcm7010006.
    1. Strati F., Cavalieri D., Albanese D., De Felice C., Donati C., Hayek J., Jousson O., Leoncini S., Renzi D., Calabro A., et al. New evidences on the altered gut microbiota in autism spectrum disorders. Microbiome. 2017;5:24. doi: 10.1186/s40168-017-0242-1.
    1. Fowlie G., Cohen N., Ming X. The perturbance of microbiome and gut-brain axis in autism spectrum disorders. Int. J. Mol. Sci. 2018;19:2251. doi: 10.3390/ijms19082251.
    1. De Angelis M., Francavilla R., Piccolo M., De Giacomo A., Gobbetti M. Autism spectrum disorders and intestinal microbiota. Gut Microbes. 2015;6:207–213. doi: 10.1080/19490976.2015.1035855.
    1. Sinaiscalco D., Brigida A.L., Antonucci N. Autism and neuro-immune-gut link. AIMS Mol. Sci. 2018;5:166–172. doi: 10.3934/molsci.2018.2.166.
    1. Wheless J.W. History of the ketogenic diet. Epilepsia. 2008;49:3–5. doi: 10.1111/j.1528-1167.2008.01821.x.
    1. Reddel S., Putignani L., Del Chierico F. The impact of low-FODMAPs, gluten-free, and ketogenic diets on gut microbiota modulation in pathological conditions. Nutrients. 2019;11:373. doi: 10.3390/nu11020373.
    1. Stafstrom C.E., Rho J.M. The ketogenic diet as a treatment paradigm for diverse neurological disorders. Front. Pharmacol. 2012;3:59. doi: 10.3389/fphar.2012.00059.
    1. Olson C.A., Vuong H.E., Yano J.M., Liang Q.Y., Nusbaum D.J., Hsiao E.Y. The gut microbiota mediates the anti-seizure effects of the ketogenic diet. Cell. 2018;173:1728–1741. doi: 10.1016/j.cell.2018.04.027.
    1. Wong C.G., Bottiglieri T., Snead O.C., III GABA, gamma-hydroxybutyric acid, and neurological disease. Ann. Neurol. 2003;54:S3–S12. doi: 10.1002/ana.10696.
    1. Doenyas C. Dietary interventions for autism spectrum disorder: New perspectives from the gut-brain axis. Physiol. Behav. 2018;194:577–582. doi: 10.1016/j.physbeh.2018.07.014.
    1. Sampson T.R., Debelius J.W., Thron T., Janssen S., Shastri G.G., Ilhan Z.E., Challis C., Schretter C.E., Rocha S., Gradinaru V., et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson’s disease. Cell. 2016;167:1469–1480. doi: 10.1016/j.cell.2016.11.018.
    1. Sarkar A., Lehto S.M., Harty S., Dinan T.G., Cryan J.F., Burnet P.W.J. Psychobiotics and the manipulation of bacteria-gut-brain signals. Trends Neurosci. 2016;39:763–781. doi: 10.1016/j.tins.2016.09.002.
    1. Skonieczna-Zydecka K., Marlicz W., Misera A., Koulaouzidis A., Loniewski I. Microbiome-the missing link in the gut-brain axis: Focus on its role in gastrointestinal and mental health. J. Clin. Med. 2018;7:521. doi: 10.3390/jcm7120521.
    1. Cammarota G., Ianiro G., Tilg H., Rajilic-Stojanovic M., Kump P., Satokari R., Sokol H., Arkkila P., Pintus C., Hart A., et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut. 2017;66:569–580. doi: 10.1136/gutjnl-2016-313017.
    1. Kang D.W., Adams J.B., Gregory A.C., Borody T., Chittick L., Fasano A., Khoruts A., Geis E., Maldonado J., McDonough-Means S., et al. Microbiota Transfer Therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: An open-label study. Microbiome. 2017;5:10. doi: 10.1186/s40168-016-0225-7.
    1. Choi H.H., Cho Y.S. Fecal microbiota transplantation: Current applications, effectiveness, and future perspectives. Clin. Endosc. 2016;49:257–265. doi: 10.5946/ce.2015.117.
    1. De Groot P.F., Frissen M.N., De Clercq N.C., Nieuwdorp M. Fecal microbiota transplantation in metabolic syndrome: History, present and future. Gut Microbes. 2017;8:253–267. doi: 10.1080/19490976.2017.1293224.
    1. Kootte R.S., Levin E., Salojarvi J., Smits L.P., Hartstra A.V., Udayappan S.D., Hermes G., Bouter K.E., Koopen A.M., Holst J.J., et al. Improvement of insulin sensitivity after lean donor feces in metabolic syndrome Is driven by baseline intestinal microbiota composition. Cell Metab. 2017;26:611–619. doi: 10.1016/j.cmet.2017.09.008.
    1. Foster J.A., Neufeld K.A.M. Gut-brain axis: How the microbiome influences anxiety and depression. Trends Neurosci. 2013;36:305–312. doi: 10.1016/j.tins.2013.01.005.
    1. Valles-Colomer M., Falony G., Darzi Y., Tigchelaar E.F., Wang J., Tito R.Y., Schiweck C., Kurilshikov A., Joossens M., Wijmenga C., et al. The neuroactive potential of the human gut microbiota in quality of life and depression. Nat. Microbiol. 2019;4:623–632. doi: 10.1038/s41564-018-0337-x.
    1. Wallace C.J.K., Milev R. The effects of probiotics on depressive symptoms in humans: A systematic review. Ann. Gen. Psychiatry. 2017;16:14. doi: 10.1186/s12991-017-0138-2.
    1. Boehme M., Van De Wouw M., Bastiaanssen T.F.S., Olavarria-Ramirez L., Lyons K., Fouhy F., Golubeva A.V., Moloney G.M., Minuto C., Sandhu K.V., et al. Mid-life microbiota crises: Middle age is associated with pervasive neuroimmune alterations that are reversed by targeting the gut microbiome. Mol. Psychiatry. 2019 doi: 10.1038/s41380-019-0425-1. in press.
    1. Banta J.E., Segovia-Siapco G., Crocker C.B., Montoya D., Alhusseini N. Mental health status and dietary intake among California adults: A population-based survey. Int. J. Food Sci. Nutr. 2019;70:759–770. doi: 10.1080/09637486.2019.1570085.
    1. Sonnenburg J.L., Backhed F. Diet-microbiota interactions as moderators of human metabolism. Nature. 2016;535:56–64. doi: 10.1038/nature18846.
    1. Ridaura V.K., Faith J.J., Rey F.E., Cheng J., Duncan A.E., Kau A.L., Griffin N.W., Lombard V., Henrissat B., Bain J.R., et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science. 2013;341:1241214. doi: 10.1126/science.1241214.
    1. Turnbaugh P.J., Ley R.E., Mahowald M.A., Magrini V., Mardis E.R., Gordon J.I. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444:1027–1031. doi: 10.1038/nature05414.
    1. Turnbaugh P.J., Hamady M., Yatsunenko T., Cantarel B.L., Duncan A., Ley R.E., Sogin M.L., Jones W.J., Roe B.A., Affourtit J.P., et al. A core gut microbiome in obese and lean twins. Nature. 2009;457:480–484. doi: 10.1038/nature07540.
    1. Le Chatelier E., Nielsen T., Qin J., Prifti E., Hildebrand F., Falony G., Almeida M., Arumugam M., Batto J.M., Kennedy S., et al. Richness of human gut microbiome correlates with metabolic markers. Nature. 2013;500:541–546. doi: 10.1038/nature12506.
    1. Cotillard A., Kennedy S.P., Kong L.C., Prifti E., Pons N., Le Chatelier E., Almeida M., Quinquis B., Levenez F., Galleron N., et al. Dietary intervention impact on gut microbial gene richness. Nature. 2013;500:585–588. doi: 10.1038/nature12480.
    1. Everard A., Belzer C., Geurts L., Ouwerkerk J.P., Druart C., Bindels L.B., Guiot Y., Derrien M., Muccioli G.G., Delzenne N.M., et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc. Natl. Acad. Sci. USA. 2013;110:9066–9071. doi: 10.1073/pnas.1219451110.
    1. Anhe F.F., Roy D., Pilon G., Dudonne S., Matamoros S., Varin T.V., Garofalo C., Moine Q., Desjardins Y., Levy E., et al. A polyphenol-rich cranberry extract protects from diet-induced obesity, insulin resistance and intestinal inflammation in association with increased Akkermansia spp. population in the gut microbiota of mice. Gut. 2015;64:872–883. doi: 10.1136/gutjnl-2014-307142.
    1. Dao M.C., Everard A., Aron-Wisnewsky J., Sokolovska N., Prifti E., Verger E.O., Kayser B.D., Levenez F., Chilloux J., Hoyles L., et al. Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: Relationship with gut microbiome richness and ecology. Gut. 2016;65:426–436. doi: 10.1136/gutjnl-2014-308778.
    1. Depommier C., Everard A., Druart C., Plovier H., Van Hul M., Vieira-Silva S., Falony G., Raes J., Maiter D., Delzenne N.M., et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: A proof-of-concept exploratory study. Nat. Med. 2019;25:1096–1103. doi: 10.1038/s41591-019-0495-2.
    1. Zhai Q., Feng S., Arjan N., Chen W. A next generation probiotic, Akkermansia muciniphila. Crit. Rev. Food Sci. Nutr. 2018 doi: 10.1080/10408398.2018.1517725. in press.
    1. Liou A.P., Paziuk M., Luevano J.M., Jr., Machineni S., Turnbaugh P.J., Kaplan L.M. Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. Sci. Transl. Med. 2013;5:178ra41. doi: 10.1126/scitranslmed.3005687.
    1. Kasubuchi M., Hasegawa S., Hiramatsu T., Ichimura A., Kimura I. Dietary gut microbial metabolites, short-chain fatty acids, and host metabolic regulation. Nutrients. 2015;7:2839–2849. doi: 10.3390/nu7042839.
    1. Zhang H., DiBaise J.K., Zuccolo A., Kudrna D., Braidotti M., Yu Y., Parameswaran P., Crowell M.D., Wing R., Rittmann B.E., et al. Human gut microbiota in obesity and after gastric bypass. Proc. Natl. Acad. Sci. USA. 2009;106:2365–2370. doi: 10.1073/pnas.0812600106.
    1. Furet J.P., Kong L.C., Tap J., Poitou C., Basdevant A., Bouillot J.L., Mariat D., Corthier G., Dore J., Henegar C., et al. Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: Links with metabolic and low-grade inflammation markers. Diabetes. 2010;59:3049–3057. doi: 10.2337/db10-0253.
    1. Jiao A.R., Diao H., Yu B., He J., Yu J., Zheng P., Huang Z.Q., Luo Y.H., Luo J.Q., Mao X.B., et al. Oral administration of short chain fatty acids could attenuate fat deposition of pigs. PLoS ONE. 2018;13:e0196867. doi: 10.1371/journal.pone.0196867.
    1. Canfora E.E., Van Der Beek C.M., Jocken J.W.E., Goossens G.H., Holst J.J., Olde Damink S.W.M., Lenaerts K., Dejong C.H.C., Blaak E.E. Colonic infusions of short-chain fatty acid mixtures promote energy metabolism in overweight/obese men: A randomized crossover trial. Sci. Rep. 2017;7:2360. doi: 10.1038/s41598-017-02546-x.
    1. Chambers E.S., Preston T., Frost G., Morrison D.J. Role of gut microbiota-generated short-chain fatty acids in metabolic and cardiovascular health. Curr. Nutr. Rep. 2018;7:198–206. doi: 10.1007/s13668-018-0248-8.
    1. Fernandes J., Su W., Rahat-Rozenbloom S., Wolever T.M., Comelli E.M. Adiposity, gut microbiota and faecal short chain fatty acids are linked in adult humans. Nutr. Diabetes. 2014;4:e121. doi: 10.1038/nutd.2014.23.
    1. Menni C., Jackson M.A., Pallister T., Steves C.J., Spector T.D., Valdes A.M. Gut microbiome diversity and high-fibre intake are related to lower long-term weight gain. Int. J. Obes. 2017;41:1099–1105. doi: 10.1038/ijo.2017.66.
    1. Li Z., Yi C.X., Katiraei S., Kooijman S., Zhou E., Chung C.K., Gao Y., Van Den Heuvel J.K., Meijer O.C., Berbee J.F.P., et al. Butyrate reduces appetite and activates brown adipose tissue via the gut-brain neural circuit. Gut. 2018;67:1269–1279. doi: 10.1136/gutjnl-2017-314050.
    1. Roshanravan N., Mahdavi R., Alizadeh E., Jafarabadi M.A., Hedayati M., Ghavami A., Alipour S., Alamdari N.M., Barati M., Ostadrahimi A. Effect of butyrate and inulin supplementation on glycemic status, lipid profile and glucagon-like peptide 1 level in patients with type 2 diabetes: A randomized double-blind, placebo-controlled trial. Horm. Metab. Res. 2017;49:886–891. doi: 10.1055/s-0043-119089.
    1. Sen T., Cawthon C.R., Ihde B.T., Hajnal A., DiLorenzo P.M., De La Serre C.B., Czaja K. Diet-driven microbiota dysbiosis is associated with vagal remodeling and obesity. Physiol. Behav. 2017;173:305–317. doi: 10.1016/j.physbeh.2017.02.027.
    1. Cani P.D., Amar J., Iglesias M.A., Poggi M., Knauf C., Bastelica D., Neyrinck A.M., Fava F., Tuohy K.M., Chabo C., et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56:1761–1772. doi: 10.2337/db06-1491.
    1. Boutagy N.E., McMillan R.P., Frisard M.I., Hulver M.W. Metabolic endotoxemia with obesity: Is it real and is it relevant? Biochimie. 2016;124:11–20. doi: 10.1016/j.biochi.2015.06.020.
    1. Pedersen C., Gallagher E., Horton F., Ellis R.J., Ijaz U.Z., Wu H., Jaiyeola E., Diribe O., Duparc T., Cani P.D., et al. Host-microbiome interactions in human type 2 diabetes following prebiotic fibre (galacto-oligosaccharide) intake. Br. J. Nutr. 2016;116:1869–1877. doi: 10.1017/S0007114516004086.
    1. Cox A.J., Zhang P., Bowden D.W., Devereaux B., Davoren P.M., Cripps A.W., West N.P. Increased intestinal permeability as a risk factor for type 2 diabetes. Diabetes Metab. 2017;43:163–166. doi: 10.1016/j.diabet.2016.09.004.
    1. Colantonio A.G., Werner S.L., Brown M. The effects of prebiotics and substances with prebiotic properties on metabolic and inflammatory biomarkers in individuals with type 2 diabetes mellitus: A systematic review. J. Acad. Nutr. Diet. 2019 doi: 10.1016/j.jand.2018.12.013. in press.
    1. Dahl W.J., Agro N.C., Eliasson A.M., Mialki K.L., Olivera J.D., Rusch C.T., Young C.N. Health benefits of fiber fermentation. J. Am. Coll. Nutr. 2017;36:127–136. doi: 10.1080/07315724.2016.1188737.
    1. Weickert M.O., Pfeiffer A.F.H. Impact of dietary fiber consumption on insulin resistance and the prevention of type 2 diabetes. J. Nutr. 2018;148:7–12. doi: 10.1093/jn/nxx008.
    1. Reynolds A., Mann J., Cummings J., Winter N., Mete E., Te Morenga L. Carbohydrate quality and human health: A series of systematic reviews and meta-analyses. Lancet. 2019;393:434–445. doi: 10.1016/S0140-6736(18)31809-9.
    1. McKenzie Y.A., Bowyer R.K., Leach H., Gulia P., Horobin J., O’Sullivan N.A., Pettitt C., Reeves L.B., Seamark L., Williams M., et al. British Dietetic Association systematic review and evidence-based practice guidelines for the dietary management of irritable bowel syndrome in adults (2016 update) J. Hum. Nutr. Diet. 2016;29:549–575. doi: 10.1111/jhn.12385.
    1. McRorie J.W., Jr. Evidence-based approach to fiber supplements and clinically meaningful health benefits, Part 1: What to look for and how to recommend an effective fiber therapy. Nutr. Today. 2015;50:82–89. doi: 10.1097/NT.0000000000000082.
    1. Lambeau K.V., McRorie J.W., Jr. Fiber supplements and clinically proven health benefits: How to recognize and recommend an effective fiber therapy. J. Am. Assoc. Nurse Pract. 2017;29:216–223. doi: 10.1002/2327-6924.12447.
    1. Jakobsdottir G., Xu J., Molin G., Ahrne S., Nyman M. High-fat diet reduces the formation of butyrate, but increases succinate, inflammation, liver fat and cholesterol in rats, while dietary fibre counteracts these effects. PLoS ONE. 2013;8:e80476. doi: 10.1371/journal.pone.0080476.
    1. Arora T., Rudenko O., Egerod K.L., Husted A.S., Kovatcheva-Datchary P., Akrami R., Kristensen M., Schwartz T.W., Backhed F. Microbial fermentation of flaxseed fibers modulates the transcriptome of GPR41-expressing enteroendocrine cells and protects mice against diet-induced obesity. Am. J. Physiol. Endocrinol. Metab. 2019;316:E453–E463. doi: 10.1152/ajpendo.00391.2018.
    1. Simpson H.L., Campbell B.J. Review article: Dietary fibre-microbiota interactions. Aliment. Pharmacol. Ther. 2015;42:158–179. doi: 10.1111/apt.13248.
    1. Zhernakova A., Kurilshikov A., Bonder M.J., Tigchelaar E.F., Schirmer M., Vatanen T., Mujagic Z., Vila A.V., Falony G., Vieira-Silva S., et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science. 2016;352:565–569. doi: 10.1126/science.aad3369.
    1. Trompette A., Gollwitzer E.S., Yadava K., Sichelstiel A.K., Sprenger N., Ngom-Bru C., Blanchard C., Junt T., Nicod L.P., Harris N.L., et al. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. Nat. Med. 2014;20:159–166. doi: 10.1038/nm.3444.
    1. Suez J., Korem T., Zeevi D., Zilberman-Schapira G., Thaiss C.A., Maza O., Israeli D., Zmora N., Gilad S., Weinberger A., et al. Artificial sweeteners induce glucose intolerance by altering the gut microbiota. Nature. 2014;514:181–186. doi: 10.1038/nature13793.
    1. Zeevi D., Korem T., Zmora N., Israeli D., Rothschild D., Weinberger A., Ben-Yacov O., Lador D., Avnit-Sagi T., Lotan-Pompan M., et al. Personalized nutrition by prediction of glycemic responses. Cell. 2015;163:1079–1094. doi: 10.1016/j.cell.2015.11.001.
    1. Mendes-Soares H., Raveh-Sadka T., Azulay S., Ben-Shlomo Y., Cohen Y., Ofek T., Stevens J., Bachrach D., Kashyap P., Segal L., et al. Model of personalized postprandial glycemic response to food developed for an Israeli cohort predicts responses in Midwestern American individuals. Am. J. Clin. Nutr. 2019;110:63–75. doi: 10.1093/ajcn/nqz028.
    1. Bashiardes S., Godneva A., Elinav E., Segal E. Towards utilization of the human genome and microbiome for personalized nutrition. Curr. Opin. Biotechnol. 2018;51:57–63. doi: 10.1016/j.copbio.2017.11.013.
    1. Qin J., Li Y., Cai Z., Li S., Zhu J., Zhang F., Liang S., Zhang W., Guan Y., Shen D., et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490:55–60. doi: 10.1038/nature11450.
    1. Wu H., Esteve E., Tremaroli V., Khan M.T., Caesar R., Manneras-Holm L., Stahlman M., Olsson L.M., Serino M., Planas-Felix M., et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat. Med. 2017;23:850–858. doi: 10.1038/nm.4345.
    1. Bauer P.V., Duca F.A., Waise T.M.Z., Rasmussen B.A., Abraham M.A., Dranse H.J., Puri A., O’Brien C.A., Lam T.K.T. Metformin alters upper small intestinal microbiota that impact a glucose-SGLT1-sensing glucoregulatory pathway. Cell Metab. 2018;27:101–117. doi: 10.1016/j.cmet.2017.09.019.
    1. De La Cuesta-Zuluaga J., Mueller N.T., Corrales-Agudelo V., Velasquez-Mejia E.P., Carmona J.A., Abad J.M., Escobar J.S. Metformin Is associated with higher relative abundance of mucin-degrading Akkermansia muciniphila and several short-chain fatty acid-producing microbiota in the gut. Diabetes Care. 2017;40:54–62. doi: 10.2337/dc16-1324.
    1. Bryrup T., Thomsen C.W., Kern T., Allin K.H., Brandslund I., Jorgensen N.R., Vestergaard H., Hansen T., Hansen T.H., Pedersen O., et al. Metformin-induced changes of the gut microbiota in healthy young men: Results of a non-blinded, one-armed intervention study. Diabetologia. 2019;62:1024–1035. doi: 10.1007/s00125-019-4848-7.
    1. Baxter N.T., Lesniak N.A., Sinani H., Schloss P.D., Koropatkin N.M. The glucoamylase inhibitor acarbose has a diet-dependent and reversible effect on the murine gut microbiome. mSphere. 2019;4:e00528-18. doi: 10.1128/mSphere.00528-18.
    1. Wang Z., Klipfell E., Bennett B.J., Koeth R., Levison B.S., Dugar B., Feldstein A.E., Britt E.B., Fu X., Chung Y.M., et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011;472:57–63. doi: 10.1038/nature09922.
    1. Gregory J.C., Buffa J.A., Org E., Wang Z., Levison B.S., Zhu W., Wagner M.A., Bennett B.J., Li L., DiDonato J.A., et al. Transmission of atherosclerosis susceptibility with gut microbial transplantation. J. Biol. Chem. 2015;290:5647–5660. doi: 10.1074/jbc.M114.618249.
    1. Tang W.H., Wang Z., Levison B.S., Koeth R.A., Britt E.B., Fu X., Wu Y., Hazen S.L. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N. Engl. J. Med. 2013;368:1575–1584. doi: 10.1056/NEJMoa1109400.
    1. Senthong V., Wang Z., Li X.S., Fan Y., Wu Y., Tang W.H., Hazen S.L. Intestinal microbiota-generated metabolite trimethylamine-N-oxide and 5-year mortality risk in stable coronary artery disease: The contributory role of intestinal microbiota in a COURAGE-like patient cohort. J. Am. Heart Assoc. 2016;5:e002816. doi: 10.1161/JAHA.115.002816.
    1. Petersen K.S., Flock M.R., Richter C.K., Mukherjea R., Slavin J.L., Kris-Etherton P.M. Healthy dietary patterns for preventing cardiometabolic disease: The role of plant-based foods and animal products. Curr. Dev. Nutr. 2017;1:e001289. doi: 10.3945/cdn.117.001289.
    1. Soliman G.A. Dietary cholesterol and the lack of evidence in cardiovascular disease. Nutrients. 2018;10:780. doi: 10.3390/nu10060780.
    1. Zhong V.W., Van Horn L., Cornelis M.C., Wilkins J.T., Ning H., Carnethon M.R., Greenland P., Mentz R.J., Tucker K.L., Zhao L., et al. Associations of dietary cholesterol or egg consumption with incident cardiovascular disease and mortality. JAMA. 2019;321:1081–1095. doi: 10.1001/jama.2019.1572.
    1. Wang Z., Roberts A.B., Buffa J.A., Levison B.S., Zhu W., Org E., Gu X., Huang Y., Zamanian-Daryoush M., Culley M.K., et al. Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis. Cell. 2015;163:1585–1595. doi: 10.1016/j.cell.2015.11.055.
    1. Chen K., Zheng X., Feng M., Li D., Zhang H. Gut microbiota-dependent metabolite trimethylamine N-oxide contributes to cardiac dysfunction in Western diet-induced obese mice. Front. Physiol. 2017;8:139. doi: 10.3389/fphys.2017.00139.
    1. Rath S., Heidrich B., Pieper D.H., Vital M. Uncovering the trimethylamine-producing bacteria of the human gut microbiota. Microbiome. 2017;5:54. doi: 10.1186/s40168-017-0271-9.
    1. Koeth R.A., Wang Z., Levison B.S., Buffa J.A., Org E., Sheehy B.T., Britt E.B., Fu X., Wu Y., Li L., et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat. Med. 2013;19:576–585. doi: 10.1038/nm.3145.
    1. Koeth R.A., Lam-Galvez B.R., Kirsop J., Wang Z., Levison B.S., Gu X., Copeland M.F., Bartlett D., Cody D.B., Dai H.J., et al. L-Carnitine in omnivorous diets induces an atherogenic gut microbial pathway in humans. J. Clin. Investig. 2019;129:373–387. doi: 10.1172/JCI94601.
    1. Alshahrani S.M., Fraser G.E., Sabate J., Knutsen R., Shavlik D., Mashchak A., Lloren J.I., Orlich M.J. Red and processed meat and mortality in a low meat intake population. Nutrients. 2019;11:622. doi: 10.3390/nu11030622.
    1. Bellavia A., Stilling F., Wolk A. High red meat intake and all-cause cardiovascular and cancer mortality: Is the risk modified by fruit and vegetable intake? Am. J. Clin. Nutr. 2016;104:1137–1143. doi: 10.3945/ajcn.116.135335.
    1. Micha R., Penalvo J.L., Cudhea F., Imamura F., Rehm C.D., Mozaffarian D. Association between dietary factors and mortality from heart disease, stroke, and type 2 diabetes in the United States. JAMA. 2017;317:912–924. doi: 10.1001/jama.2017.0947.
    1. Micha R., Wallace S.K., Mozaffarian D. Red and processed meat consumption and risk of incident coronary heart disease, stroke, and diabetes mellitus: A systematic review and meta-analysis. Circulation. 2010;121:2271–2283. doi: 10.1161/CIRCULATIONAHA.109.924977.
    1. Guasch-Ferre M., Satija A., Blondin S.A., Janiszewski M., Emlen E., O’Connor L.E., Campbell W.W., Hu F.B., Willett W.C., Stampfer M.J. Meta-analysis of randomized controlled trials of red meat consumption in comparison with various comparison diets on cardiovascular risk factors. Circulation. 2019;139:1828–1845. doi: 10.1161/CIRCULATIONAHA.118.035225.
    1. Hills R.D., Jr., Erpenbeck E. Guide to popular diets, food choices, and their health outcome. Health Care Curr. Rev. 2018;6:223. doi: 10.4172/2375-4273.1000223.
    1. Jin Q., Black A., Kales S.N., Vattem D., Ruiz-Canela M., Sotos-Prieto M. Metabolomics and microbiomes as potential tools to evaluate the effects of the Mediterranean diet. Nutrients. 2019;11:207. doi: 10.3390/nu11010207.
    1. Lara K.M., Levitan E.B., Gutierrez O.M., Shikany J.M., Safford M.M., Judd S.E., Rosenson R.S. Dietary patterns and incident heart failure in U.S. adults without known coronary disease. J. Am. Coll. Cardiol. 2019;73:2036–2045. doi: 10.1016/j.jacc.2019.01.067.
    1. Grosso G., Marventano S., Yang J., Micek A., Pajak A., Scalfi L., Galvano F., Kales S.N. A comprehensive meta-analysis on evidence of Mediterranean diet and cardiovascular disease: Are individual components equal? Crit. Rev. Food Sci. Nutr. 2017;57:3218–3232. doi: 10.1080/10408398.2015.1107021.
    1. De Filippis F., Pellegrini N., Vannini L., Jeffery I.B., La Storia A., Laghi L., Serrazanetti D.I., Di Cagno R., Ferrocino I., Lazzi C., et al. High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome. Gut. 2016;65:1812–1821. doi: 10.1136/gutjnl-2015-309957.
    1. Alexander D.D., Weed D.L., Miller P.E., Mohamed M.A. Red meat and colorectal cancer: A quantitative update on the state of the epidemiologic science. J. Am. Coll. Nutr. 2015;34:521–543. doi: 10.1080/07315724.2014.992553.
    1. Schwingshackl L., Schwedhelm C., Galbete C., Hoffmann G. Adherence to Mediterranean Diet and risk of cancer: An updated systematic review and meta-analysis. Nutrients. 2017;9:1063. doi: 10.3390/nu9101063.
    1. Thomas A.M., Manghi P., Asnicar F., Pasolli E., Armanini F., Zolfo M., Beghini F., Manara S., Karcher N., Pozzi C., et al. Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a link with choline degradation. Nat. Med. 2019;25:667–678. doi: 10.1038/s41591-019-0405-7.
    1. Wirbel J., Pyl P.T., Kartal E., Zych K., Kashani A., Milanese A., Fleck J.S., Voigt A.Y., Palleja A., Ponnudurai R., et al. Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer. Nat. Med. 2019;25:679–689. doi: 10.1038/s41591-019-0406-6.
    1. Youn J., Cho E., Lee J.E. Association of choline and betaine levels with cancer incidence and survival: A meta-analysis. Clin. Nutr. 2019;38:100–109. doi: 10.1016/j.clnu.2018.01.042.
    1. Bishehsari F., Engen P.A., Preite N.Z., Tuncil Y.E., Naqib A., Shaikh M., Rossi M., Wilber S., Green S.J., Hamaker B.R., et al. Dietary fiber treatment corrects the composition of gut microbiota, promotes SCFA production, and suppresses colon carcinogenesis. Genes. 2018;9:102. doi: 10.3390/genes9020102.
    1. Song Y., Liu M., Yang F.G., Cui L.H., Lu X.Y., Chen C. Dietary fibre and the risk of colorectal cancer: A case- control study. Asian Pac. J. Cancer Prev. 2015;16:3747–3752. doi: 10.7314/APJCP.2015.16.9.3747.
    1. Zhang F.F., Cudhea F., Shan Z., Michaud D.S., Imamura F., Eom H., Ruan M., Rehm C.D., Liu J., Du M., et al. Preventable cancer burden associated with poor diet in the United States. JNCI Cancer Spectr. 2019;3:pkz034. doi: 10.1093/jncics/pkz034.
    1. Vonaesch P., Anderson M., Sansonetti P.J. Pathogens, microbiome and the host: Emergence of the ecological Koch’s postulates. FEMS Microbiol. Rev. 2018;42:273–292. doi: 10.1093/femsre/fuy003.
    1. Tomkovich S., Dejea C.M., Winglee K., Drewes J.L., Chung L., Housseau F., Pope J.L., Gauthier J., Sun X., Muhlbauer M., et al. Human colon mucosal biofilms from healthy or colon cancer hosts are carcinogenic. J. Clin. Investig. 2019;130:1699–1712. doi: 10.1172/JCI124196.
    1. Hill C., Guarner F., Reid G., Gibson G.R., Merenstein D.J., Pot B., Morelli L., Canani R.B., Flint H.J., Salminen S., et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat. Rev. Gastroenterol. Hepatol. 2014;11:506–514. doi: 10.1038/nrgastro.2014.66.
    1. Shen J., Zuo Z.X., Mao A.P. Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn’s disease, and pouchitis: Meta-analysis of randomized controlled trials. Inflamm. Bowel Dis. 2014;20:21–35. doi: 10.1097/.
    1. Wilkins T., Sequoia J. Probiotics for gastrointestinal conditions: A summary of the evidence. Am. Fam. Physician. 2017;96:170–178.
    1. Tojo R., Suarez A., Clemente M.G., De Los Reyes-Gavilan C.G., Margolles A., Gueimonde M., Ruas-Madiedo P. Intestinal microbiota in health and disease: Role of bifidobacteria in gut homeostasis. World J. Gastroenterol. 2014;20:15163–15176. doi: 10.3748/wjg.v20.i41.15163.
    1. Sanchez B., Delgado S., Blanco-Miguez A., Lourenco A., Gueimonde M., Margolles A. Probiotics, gut microbiota, and their influence on host health and disease. Mol. Nutr. Food Res. 2017;61:1600240. doi: 10.1002/mnfr.201600240.
    1. Allen S.J., Martinez E.G., Gregorio G.V., Dans L.F. Probiotics for treating acute infectious diarrhoea. Cochrane Database Syst. Rev. 2010;11:CD003048. doi: 10.1002/14651858.CD003048.pub3.
    1. Goldenberg J.Z., Yap C., Lytvyn L., Lo C.K., Beardsley J., Mertz D., Johnston B.C. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst. Rev. 2017;12:CD006095. doi: 10.1002/14651858.CD006095.pub4.
    1. Goldenberg J.Z., Mertz D., Johnston B.C. Probiotics to prevent Clostridium difficile infection in patients receiving antibiotics. JAMA. 2018;320:499–500. doi: 10.1001/jama.2018.9064.
    1. Fijan S. Microorganisms with claimed probiotic properties: An overview of recent literature. Int. J. Env. Res. Public Health. 2014;11:4745–4767. doi: 10.3390/ijerph110504745.
    1. Dimidi E., Christodoulides S., Scott S.M., Whelan K. Mechanisms of action of probiotics and the gastrointestinal microbiota on gut motility and constipation. Adv. Nutr. 2017;8:484–494. doi: 10.3945/an.116.014407.
    1. Plaza-Diaz J., Ruiz-Ojeda F.J., Gil-Campos M., Gil A. Mechanisms of action of probiotics. Adv. Nutr. 2019;10:S49–S66. doi: 10.1093/advances/nmy063.
    1. LeBlanc J.G., Chain F., Martin R., Bermudez-Humaran L.G., Courau S., Langella P. Beneficial effects on host energy metabolism of short-chain fatty acids and vitamins produced by commensal and probiotic bacteria. Microb. Cell Fact. 2017;16:79. doi: 10.1186/s12934-017-0691-z.
    1. Ford A.C., Quigley E.M., Lacy B.E., Lembo A.J., Saito Y.A., Schiller L.R., Soffer E.E., Spiegel B.M., Moayyedi P. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: Systematic review and meta-analysis. Am. J. Gastroenterol. 2014;109:1547–1561. doi: 10.1038/ajg.2014.202.
    1. Rajilic-Stojanovic M., Biagi E., Heilig H.G., Kajander K., Kekkonen R.A., Tims S., De Vos W.M. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology. 2011;141:1792–1801. doi: 10.1053/j.gastro.2011.07.043.
    1. O’Callaghan A., Van Sinderen D. Bifidobacteria and their role as members of the human gut microbiota. Front. Microbiol. 2016;7:925. doi: 10.3389/fmicb.2016.00925.
    1. Giamarellos-Bourboulis E.J., Pyleris E., Barbatzas C., Pistiki A., Pimentel M. Small intestinal bacterial overgrowth is associated with irritable bowel syndrome and is independent of proton pump inhibitor usage. BMC Gastroenterol. 2016;16:67. doi: 10.1186/s12876-016-0484-6.
    1. Saffouri G.B., Shields-Cutler R.R., Chen J., Yang Y., Lekatz H.R., Hale V.L., Cho J.M., Battaglioli E.J., Bhattarai Y., Thompson K.J., et al. Small intestinal microbial dysbiosis underlies symptoms associated with functional gastrointestinal disorders. Nat. Commun. 2019;10:2012. doi: 10.1038/s41467-019-09964-7.
    1. De Simone C. The unregulated probiotic market. Clin. Gastroenterol. Hepatol. 2018;17:809–817. doi: 10.1016/j.cgh.2018.01.018.
    1. Campana R., Van Hemert S., Baffone W. Strain-specific probiotic properties of lactic acid bacteria and their interference with human intestinal pathogens invasion. Gut Pathog. 2017;9:12. doi: 10.1186/s13099-017-0162-4.
    1. Wang L., Hu L., Xu Q., Yin B., Fang D., Wang G., Zhao J., Zhang H., Chen W. Bifidobacterium adolescentis exerts strain-specific effects on constipation induced by loperamide in BALB/c mice. Int. J. Mol. Sci. 2017;18:318. doi: 10.3390/ijms18020318.
    1. Conway T., Cohen P.S. Commensal and pathogenic Escherichia coli metabolism in the gut. Microbiol. Spectr. 2015;3 doi: 10.1128/microbiolspec.MBP-0006-2014.
    1. Goswami K., Chen C., Xiaoli L., Eaton K.A., Dudley E.G. Coculture of Escherichia coli O157:H7 with a nonpathogenic E. coli strain increases toxin production and virulence in a germfree mouse model. Infect. Immun. 2015;83:4185–4193. doi: 10.1128/IAI.00663-15.
    1. Crook N., Ferreiro A., Gasparrini A.J., Pesesky M.W., Gibson M.K., Wang B., Sun X., Condiotte Z., Dobrowolski S., Peterson D., et al. Adaptive strategies of the candidate probiotic E. coli Nissle in the mammalian gut. Cell Host Microbe. 2019;25:499–512. doi: 10.1016/j.chom.2019.02.005.
    1. Lerner A., Matthias T., Aminov R. Potential effects of horizontal gene exchange in the human gut. Front. Immunol. 2017;8:1630. doi: 10.3389/fimmu.2017.01630.
    1. Trinchieri V., Laghi L., Vitali B., Parolin C., Giusti I., Capobianco D., Mastromarino P., De Simone C. Efficacy and safety of a multistrain probiotic formulation depends from manufacturing. Front. Immunol. 2017;8:1474. doi: 10.3389/fimmu.2017.01474.
    1. Hod K., Dekel R., Aviv Cohen N., Sperber A., Ron Y., Boaz M., Berliner S., Maharshak N. The effect of a multispecies probiotic on microbiota composition in a clinical trial of patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol. Motil. 2018;30:e13456. doi: 10.1111/nmo.13456.
    1. Lee S.H., Joo N.S., Kim K.M., Kim K.N. The therapeutic effect of a multistrain probiotic on diarrhea-predominant irritable bowel syndrome: A pilot study. Gastroenterol. Res. Pract. 2018;2018:8791916. doi: 10.1155/2018/8791916.
    1. Plaza-Diaz J., Ruiz-Ojeda F.J., Vilchez-Padial L.M., Gil A. Evidence of the anti-inflammatory effects of probiotics and synbiotics in intestinal chronic diseases. Nutrients. 2017;9:555. doi: 10.3390/nu9060555.
    1. Floch M.H., Walker W.A., Sanders M.E., Nieuwdorp M., Kim A.S., Brenner D.A., Qamar A.A., Miloh T.A., Guarino A., Guslandi M., et al. Recommendations for probiotic use--2015 Update: Proceedings and consensus opinion. J. Clin. Gastroenterol. 2015;49:S69–S73. doi: 10.1097/MCG.0000000000000420.
    1. Markowiak P., Slizewska K. Effects of probiotics, prebiotics, and synbiotics on human health. Nutrients. 2017;9:1021. doi: 10.3390/nu9091021.
    1. Hughes K.R., Harnisch L.C., Alcon-Giner C., Mitra S., Wright C.J., Ketskemety J., Van Sinderen D., Watson A.J., Hall L.J. Bifidobacterium breve reduces apoptotic epithelial cell shedding in an exopolysaccharide and MyD88-dependent manner. Open Biol. 2017;7:160155. doi: 10.1098/rsob.160155.
    1. Lam Y.Y., Ha C.W., Campbell C.R., Mitchell A.J., Dinudom A., Oscarsson J., Cook D.I., Hunt N.H., Caterson I.D., Holmes A.J., et al. Increased gut permeability and microbiota change associate with mesenteric fat inflammation and metabolic dysfunction in diet-induced obese mice. PLoS ONE. 2012;7:e34233. doi: 10.1371/journal.pone.0034233.
    1. Wang Y., Kirpich I., Liu Y., Ma Z., Barve S., McClain C.J., Feng W. Lactobacillus rhamnosus GG treatment potentiates intestinal hypoxia-inducible factor, promotes intestinal integrity and ameliorates alcohol-induced liver injury. Am. J. Pathol. 2011;179:2866–2875. doi: 10.1016/j.ajpath.2011.08.039.
    1. Reid G. Probiotics to prevent the need for, and augment the use of, antibiotics. Can. J. Infect. Dis. Med. Microbiol. 2006;17:219–295. doi: 10.1155/2006/934626.
    1. Sherman P.M., Johnson-Henry K.C., Yeung H.P., Ngo P.S., Goulet J., Tompkins T.A. Probiotics reduce enterohemorrhagic Escherichia coli O157:H7- and enteropathogenic E. coli O127:H6-induced changes in polarized T84 epithelial cell monolayers by reducing bacterial adhesion and cytoskeletal rearrangements. Infect. Immun. 2005;73:5183–5188. doi: 10.1128/IAI.73.8.5183-5188.2005.
    1. Ferrario C., Taverniti V., Milani C., Fiore W., Laureati M., De Noni I., Stuknyte M., Chouaia B., Riso P., Guglielmetti S. Modulation of fecal Clostridiales bacteria and butyrate by probiotic intervention with Lactobacillus paracasei DG varies among healthy adults. J. Nutr. 2014;144:1787–1796. doi: 10.3945/jn.114.197723.
    1. Barbara G., Cremon C., Azpiroz F. Probiotics in irritable bowel syndrome: Where are we? Neurogastroenterol. Motil. 2018;30:e13513. doi: 10.1111/nmo.13513.
    1. Baxter N.T., Schmidt A.W., Venkataraman A., Kim K.S., Waldron C., Schmidt T.M. Dynamics of human gut microbiota and short-chain fatty acids in response to dietary interventions with three fermentable fibers. mBio. 2019;10:e02566-18. doi: 10.1128/mBio.02566-18.
    1. Bordalo Tonucci L., Dos Santos K.M., De Luces Fortes Ferreira C.L., Ribeiro S.M., De Oliveira L.L., Martino H.S. Gut microbiota and probiotics: Focus on diabetes mellitus. Crit. Rev. Food Sci. Nutr. 2017;57:2296–2309. doi: 10.1080/10408398.2014.934438.
    1. Sanchez M., Darimont C., Drapeau V., Emady-Azar S., Lepage M., Rezzonico E., Ngom-Bru C., Berger B., Philippe L., Ammon-Zuffrey C., et al. Effect of Lactobacillus rhamnosus CGMCC1.3724 supplementation on weight loss and maintenance in obese men and women. Br. J. Nutr. 2014;111:1507–1519. doi: 10.1017/S0007114513003875.
    1. Sabico S., Al-Mashharawi A., Al-Daghri N.M., Wani K., Amer O.E., Hussain D.S., Ahmed Ansari M.G., Masoud M.S., Alokail M.S., McTernan P.G. Effects of a 6-month multi-strain probiotics supplementation in endotoxemic, inflammatory and cardiometabolic status of T2DM patients: A randomized, double-blind, placebo-controlled trial. Clin. Nutr. 2018;38:1561–1569. doi: 10.1016/j.clnu.2018.08.009.
    1. Abildgaard A., Elfving B., Hokland M., Wegener G., Lund S. Probiotic treatment reduces depressive-like behaviour in rats independently of diet. Psychoneuroendocrinology. 2017;79:40–48. doi: 10.1016/j.psyneuen.2017.02.014.
    1. Kadooka Y., Sato M., Ogawa A., Miyoshi M., Uenishi H., Ogawa H., Ikuyama K., Kagoshima M., Tsuchida T. Effect of Lactobacillus gasseri SBT2055 in fermented milk on abdominal adiposity in adults in a randomised controlled trial. Br. J. Nutr. 2013;110:1696–1703. doi: 10.1017/S0007114513001037.
    1. Kim J., Yun J.M., Kim M.K., Kwon O., Cho B. Lactobacillus gasseri BNR17 supplementation reduces the visceral fat accumulation and waist circumference in obese adults: A randomized, double-blind, placebo-controlled trial. J. Med. Food. 2018;21:454–461. doi: 10.1089/jmf.2017.3937.
    1. Valcheva R., Dieleman L.A. Prebiotics: Definition and protective mechanisms. Best Pract. Res. Clin. Gastroenterol. 2016;30:27–37. doi: 10.1016/j.bpg.2016.02.008.
    1. Nie Y., Lin Q., Luo F. Effects of non-starch polysaccharides on inflammatory bowel disease. Int. J. Mol. Sci. 2017;18:1372. doi: 10.3390/ijms18071372.
    1. Ruiz-Ojeda F.J., Plaza-Diaz J., Saez-Lara M.J., Gil A. Effects of sweeteners on the gut microbiota: A review of experimental studies and clinical trials. Adv. Nutr. 2019;10:S31–S48. doi: 10.1093/advances/nmy037.
    1. Leenen C.H., Dieleman L.A. Inulin and oligofructose in chronic inflammatory bowel disease. J. Nutr. 2007;137:2572S–2575S. doi: 10.1093/jn/137.11.2572S.
    1. Musilova S., Rada V., Marounek M., Nevoral J., Duskova D., Bunesova V., Vlkova E., Zelenka R. Prebiotic effects of a novel combination of galactooligosaccharides and maltodextrins. J. Med. Food. 2015;18:685–689. doi: 10.1089/jmf.2013.0187.
    1. Nicolucci A.C., Hume M.P., Martinez I., Mayengbam S., Walter J., Reimer R.A. Prebiotics reduce body fat and alter intestinal microbiota in children who are overweight or with obesity. Gastroenterology. 2017;153:711–722. doi: 10.1053/j.gastro.2017.05.055.
    1. Rios J.L., Bomhof M.R., Reimer R.A., Hart D.A., Collins K.H., Herzog W. Protective effect of prebiotic and exercise intervention on knee health in a rat model of diet-induced obesity. Sci. Rep. 2019;9:3893. doi: 10.1038/s41598-019-40601-x.
    1. Chen T., Long W., Zhang C., Liu S., Zhao L., Hamaker B.R. Fiber-utilizing capacity varies in Prevotella- versus Bacteroides-dominated gut microbiota. Sci. Rep. 2017;7:2594. doi: 10.1038/s41598-017-02995-4.
    1. Thomas S., Browne H., Mobasheri A., Rayman M.P. What is the evidence for a role for diet and nutrition in osteoarthritis? Rheumatology. 2018;57:iv61–iv74. doi: 10.1093/rheumatology/key011.
    1. Watson H., Mitra S., Croden F.C., Taylor M., Wood H.M., Perry S.L., Spencer J.A., Quirke P., Toogood G.J., Lawton C.L., et al. A randomised trial of the effect of omega-3 polyunsaturated fatty acid supplements on the human intestinal microbiota. Gut. 2018;67:1974–1983. doi: 10.1136/gutjnl-2017-314968.
    1. Costantini L., Molinari R., Farinon B., Merendino N. Impact of omega-3 fatty acids on the gut microbiota. Int. J. Mol. Sci. 2017;18:2645. doi: 10.3390/ijms18122645.
    1. Menni C., Zierer J., Pallister T., Jackson M.A., Long T., Mohney R.P., Steves C.J., Spector T.D., Valdes A.M. Omega-3 fatty acids correlate with gut microbiome diversity and production of N-carbamylglutamate in middle aged and elderly women. Sci. Rep. 2017;7:11079. doi: 10.1038/s41598-017-10382-2.
    1. Kim Y., Je Y., Giovannucci E. Coffee consumption and all-cause and cause-specific mortality: A meta-analysis by potential modifiers. Eur. J. Epidemiol. 2019;34:731–752. doi: 10.1007/s10654-019-00524-3.
    1. Falony G., Joossens M., Vieira-Silva S., Wang J., Darzi Y., Faust K., Kurilshikov A., Bonder M.J., Valles-Colomer M., Vandeputte D., et al. Population-level analysis of gut microbiome variation. Science. 2016;352:560–564. doi: 10.1126/science.aad3503.
    1. Vandeputte D., Falony G., Vieira-Silva S., Tito R.Y., Joossens M., Raes J. Stool consistency is strongly associated with gut microbiota richness and composition, enterotypes and bacterial growth rates. Gut. 2016;65:57–62. doi: 10.1136/gutjnl-2015-309618.
    1. Tropini C., Moss E.L., Merrill B.D., Ng K.M., Higginbottom S.K., Casavant E.P., Gonzalez C.G., Fremin B., Bouley D.M., Elias J.E., et al. Transient osmotic perturbation causes long-term alteration to the gut microbiota. Cell. 2018;173:1742–1754. doi: 10.1016/j.cell.2018.05.008.
    1. Lee S.H., Yun Y., Kim S.J., Lee E.J., Chang Y., Ryu S., Shin H., Kim H.L., Kim H.N., Lee J.H. Association between cigarette smoking status and composition of gut microbiota: Population-based cross-sectional study. J. Clin. Med. 2018;7:282. doi: 10.3390/jcm7090282.
    1. Song S.J., Lauber C., Costello E.K., Lozupone C.A., Humphrey G., Berg-Lyons D., Caporaso J.G., Knights D., Clemente J.C., Nakielny S., et al. Cohabiting family members share microbiota with one another and with their dogs. eLife. 2013;2:e00458. doi: 10.7554/eLife.00458.
    1. Parajuli A., Gronroos M., Siter N., Puhakka R., Vari H.K., Roslund M.I., Jumpponen A., Nurminen N., Laitinen O.H., Hyoty H., et al. Urbanization reduces transfer of diverse environmental microbiota indoors. Front. Microbiol. 2018;9:84. doi: 10.3389/fmicb.2018.00084.
    1. Mahnert A., Moissl-Eichinger C., Zojer M., Bogumil D., Mizrahi I., Rattei T., Martinez J.L., Berg G. Man-made microbial resistances in built environments. Nat. Commun. 2019;10:968. doi: 10.1038/s41467-019-08864-0.
    1. Fragiadakis G.K., Smits S.A., Sonnenburg E.D., Van Treuren W., Reid G., Knight R., Manjurano A., Changalucha J., Dominguez-Bello M.G., Leach J., et al. Links between environment, diet, and the hunter-gatherer microbiome. Gut Microbes. 2019;10:216–227. doi: 10.1080/19490976.2018.1494103.
    1. Fu J., Bonder M.J., Cenit M.C., Tigchelaar E.F., Maatman A., Dekens J.A., Brandsma E., Marczynska J., Imhann F., Weersma R.K., et al. The gut microbiome contributes to a substantial proportion of the variation in blood lipids. Circ. Res. 2015;117:817–824. doi: 10.1161/CIRCRESAHA.115.306807.
    1. Elshazly M.B., Martin S.S., Blaha M.J., Joshi P.H., Toth P.P., McEvoy J.W., Al-Hijji M.A., Kulkarni K.R., Kwiterovich P.O., Blumenthal R.S., et al. Non-high-density lipoprotein cholesterol, guideline targets, and population percentiles for secondary prevention in 1.3 million adults: The VLDL-2 study (very large database of lipids) J. Am. Coll. Cardiol. 2013;62:1960–1965. doi: 10.1016/j.jacc.2013.07.045.
    1. Ravnskov U., De Lorgeril M., Diamond D.M., Hama R., Hamazaki T., Hammarskjold B., Hynes N., Kendrick M., Langsjoen P.H., Mascitelli L., et al. LDL-C does not cause cardiovascular disease: A comprehensive review of the current literature. Expert Rev. Clin. Pharmacol. 2018;11:959–970. doi: 10.1080/17512433.2018.1519391.
    1. Wu T.T., Zheng Y.Y., Yang Y.N., Li X.M., Ma Y.T., Xie X. Age, sex, and cardiovascular risk attributable to lipoprotein cholesterol among chinese individuals with coronary artery disease: A case-control study. Metab. Syndr. Relat. Disord. 2019;17:223–231. doi: 10.1089/met.2018.0067.
    1. Ference B.A., Ginsberg H.N., Graham I., Ray K.K., Packard C.J., Bruckert E., Hegele R.A., Krauss R.M., Raal F.J., Schunkert H., et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur. Heart J. 2017;38:2459–2472. doi: 10.1093/eurheartj/ehx144.
    1. Kastelein J.J., Van Der Steeg W.A., Holme I., Gaffney M., Cater N.B., Barter P., Deedwania P., Olsson A.G., Boekholdt S.M., Demicco D.A., et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation. 2008;117:3002–3009. doi: 10.1161/CIRCULATIONAHA.107.713438.
    1. Meeusen J.W., Donato L.J., Jaffe A.S. Should apolipoprotein B replace LDL cholesterol as therapeutic targets are lowered? Curr. Opin. Lipidol. 2016;27:359–366. doi: 10.1097/MOL.0000000000000313.
    1. Greene C.M., Waters D., Clark R.M., Contois J.H., Fernandez M.L. Plasma LDL and HDL characteristics and carotenoid content are positively influenced by egg consumption in an elderly population. Nutr. Metab. 2006;3:6. doi: 10.1186/1743-7075-3-6.
    1. Willeit P., Ridker P.M., Nestel P.J., Simes J., Tonkin A.M., Pedersen T.R., Schwartz G.G., Olsson A.G., Colhoun H.M., Kronenberg F., et al. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: Individual patient-data meta-analysis of statin outcome trials. Lancet. 2018;392:1311–1320. doi: 10.1016/S0140-6736(18)31652-0.
    1. Tsimikas S., Gordts P., Nora C., Yeang C., Witztum J.L. Statin therapy increases lipoprotein(a) levels. Eur. Heart J. 2019 doi: 10.1093/eurheartj/ehz310. in press.
    1. Choi C.U., Seo H.S., Lee E.M., Shin S.Y., Choi U.J., Na J.O., Lim H.E., Kim J.W., Kim E.J., Rha S.W., et al. Statins do not decrease small, dense low-density lipoprotein. Tex. Heart Inst. J. 2010;37:421–428.
    1. Magge S., Lembo A. Low-FODMAP diet for treatment of irritable bowel syndrome. Gastroenterol. Hepatol. 2012;8:739–745.
    1. Skodje G.I., Sarna V.K., Minelle I.H., Rolfsen K.L., Muir J.G., Gibson P.R., Veierod M.B., Henriksen C., Lundin K.E.A. Fructan, rather than gluten, induces symptoms in patients with self-reported non-Celiac gluten sensitivity. Gastroenterology. 2018;154:529–539. doi: 10.1053/j.gastro.2017.10.040.
    1. Biesiekierski J.R., Peters S.L., Newnham E.D., Rosella O., Muir J.G., Gibson P.R. No effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates. Gastroenterology. 2013;145:320–328. doi: 10.1053/j.gastro.2013.04.051.
    1. Fasano A., Sapone A., Zevallos V., Schuppan D. Nonceliac gluten sensitivity. Gastroenterology. 2015;148:1195–1204. doi: 10.1053/j.gastro.2014.12.049.
    1. Halmos E.P., Gibson P.R. Controversies and reality of the FODMAP diet for patients with irritable bowel syndrome. J. Gastroenterol. Hepatol. 2019 doi: 10.1111/jgh.14650. in press.
    1. Staudacher H.M., Ralph F.S.E., Irving P.M., Whelan K., Lomer M.C.E. Nutrient intake, diet quality, and diet diversity in irritable bowel syndrome and the impact of the low FODMAP diet. J. Acad. Nutr. Diet. 2019 doi: 10.1016/j.jand.2019.01.017. in press.
    1. Claesson M.J., Jeffery I.B., Conde S., Power S.E., O’Connor E.M., Cusack S., Harris H.M., Coakley M., Lakshminarayanan B., O’Sullivan O., et al. Gut microbiota composition correlates with diet and health in the elderly. Nature. 2012;488:178–184. doi: 10.1038/nature11319.
    1. Halmos E.P., Christophersen C.T., Bird A.R., Shepherd S.J., Gibson P.R., Muir J.G. Diets that differ in their FODMAP content alter the colonic luminal microenvironment. Gut. 2015;64:93–100. doi: 10.1136/gutjnl-2014-307264.
    1. Dieterich W., Schuppan D., Schink M., Schwappacher R., Wirtz S., Agaimy A., Neurath M.F., Zopf Y. Influence of low FODMAP and gluten-free diets on disease activity and intestinal microbiota in patients with non-celiac gluten sensitivity. Clin. Nutr. 2019;38:697–707. doi: 10.1016/j.clnu.2018.03.017.
    1. Kosinski C., Jornayvaz F.R. Effects of ketogenic diets on cardiovascular risk factors: Evidence from animal and human studies. Nutrients. 2017;9:517. doi: 10.3390/nu9050517.
    1. Ebbeling C.B., Feldman H.A., Klein G.L., Wong J.M.W., Bielak L., Steltz S.K., Luoto P.K., Wolfe R.R., Wong W.W., Ludwig D.S. Effects of a low carbohydrate diet on energy expenditure during weight loss maintenance: Randomized trial. BMJ. 2018;363:k4583. doi: 10.1136/bmj.k4583.
    1. De Koning L., Fung T.T., Liao X., Chiuve S.E., Rimm E.B., Willett W.C., Spiegelman D., Hu F.B. Low-carbohydrate diet scores and risk of type 2 diabetes in men. Am. J. Clin. Nutr. 2011;93:844–850. doi: 10.3945/ajcn.110.004333.
    1. Seidelmann S.B., Claggett B., Cheng S., Henglin M., Shah A., Steffen L.M., Folsom A.R., Rimm E.B., Willett W.C., Solomon S.D. Dietary carbohydrate intake and mortality: A prospective cohort study and meta-analysis. Lancet Public Health. 2018;3:e419–e428. doi: 10.1016/S2468-2667(18)30135-X.
    1. Swidsinski A., Dorffel Y., Loening-Baucke V., Gille C., Goktas O., Reisshauer A., Neuhaus J., Weylandt K.H., Guschin A., Bock M. Reduced mass and diversity of the colonic microbiome in patients with multiple sclerosis and their improvement with ketogenic diet. Front. Microbiol. 2017;8:1141. doi: 10.3389/fmicb.2017.01141.
    1. Zhang Y., Zhou S., Zhou Y., Yu L., Zhang L., Wang Y. Altered gut microbiome composition in children with refractory epilepsy after ketogenic diet. Epilepsy Res. 2018;145:163–168. doi: 10.1016/j.eplepsyres.2018.06.015.
    1. Kearns C.E., Apollonio D., Glantz S.A. Sugar industry sponsorship of germ-free rodent studies linking sucrose to hyperlipidemia and cancer: An historical analysis of internal documents. PLoS Biol. 2017;15:e2003460. doi: 10.1371/journal.pbio.2003460.
    1. Hoffmann C., Dollive S., Grunberg S., Chen J., Li H., Wu G.D., Lewis J.D., Bushman F.D. Archaea and fungi of the human gut microbiome: Correlations with diet and bacterial residents. PLoS ONE. 2013;8:e66019. doi: 10.1371/journal.pone.0066019.
    1. Samuel B.S., Gordon J.I. A humanized gnotobiotic mouse model of host-archaeal-bacterial mutualism. Proc. Natl. Acad. Sci. USA. 2006;103:10011–10016. doi: 10.1073/pnas.0602187103.
    1. McNeil N.I. The contribution of the large intestine to energy supplies in man. Am. J. Clin. Nutr. 1984;39:338–342. doi: 10.1093/ajcn/39.2.338.
    1. Ghoshal U., Shukla R., Srivastava D., Ghoshal U.C. Irritable bowel syndrome, particularly the constipation-predominant form, involves an increase in Methanobrevibacter smithii, which is associated with higher methane production. Gut Liver. 2016;10:932–938. doi: 10.5009/gnl15588.
    1. Hallen-Adams H.E., Suhr M.J. Fungi in the healthy human gastrointestinal tract. Virulence. 2017;8:352–358. doi: 10.1080/21505594.2016.1247140.
    1. Otasevic S., Momcilovic S., Petrovic M., Radulovic O., Stojanovic N.M., Arsic-Arsenijevic V. The dietary modification and treatment of intestinal Candida overgrowth - a pilot study. J. Mycol. Med. 2018;28:623–627. doi: 10.1016/j.mycmed.2018.08.002.
    1. Bertolini M., Ranjan A., Thompson A., Diaz P.I., Sobue T., Maas K., Dongari-Bagtzoglou A. Candida albicans induces mucosal bacterial dysbiosis that promotes invasive infection. PLoS Pathog. 2019;15:e1007717. doi: 10.1371/journal.ppat.1007717.
    1. Cottier F., Tan A.S., Xu X., Wang Y., Pavelka N. MIG1 regulates resistance of Candida albicans against the fungistatic effect of weak organic acids. Eukaryot. Cell. 2015;14:1054–1061. doi: 10.1128/EC.00129-15.
    1. Allonsius C.N., Van Den Broek M.F.L., De Boeck I., Kiekens S., Oerlemans E.F.M., Kiekens F., Foubert K., Vandenheuvel D., Cos P., Delputte P., et al. Interplay between Lactobacillus rhamnosus GG and Candida and the involvement of exopolysaccharides. Microb. Biotechnol. 2017;10:1753–1763. doi: 10.1111/1751-7915.12799.
    1. Haas S.V., Haas M.P. The treatment of celiac disease with the specific carbohydrate diet; report on 191 additional cases. Am. J. Gastroenterol. 1955;23:344–360.
    1. Breaking the Vicious Cycle and the Specific Carbohydrate Diet. [(accessed on 14 July 2019)]; Available online: .
    1. Gottschall E. Breaking the Vicious Cycle: Intestinal Health Through Diet. Kirkton Press; Baltimore, ON, Canada: 1994. p. 205.
    1. Nutrition in Immune Balance (NiMBAL)—Food Table. [(accessed on 26 June 2019)]; Available online: .
    1. Kakodkar S., Farooqui A.J., Mikolaitis S.L., Mutlu E.A. The specific carbohydrate diet for inflammatory bowel disease: A case series. J. Acad. Nutr. Diet. 2015;115:1226–1232. doi: 10.1016/j.jand.2015.04.016.
    1. Chassaing B., Koren O., Goodrich J.K., Poole A.C., Srinivasan S., Ley R.E., Gewirtz A.T. Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. Nature. 2015;519:92–96. doi: 10.1038/nature14232.
    1. Chassaing B., Raja S.M., Lewis J.D., Srinivasan S., Gewirtz A.T. Colonic microbiota encroachment correlates with dysglycemia in humans. Cell. Mol. Gastroenterol. Hepatol. 2017;4:205–221. doi: 10.1016/j.jcmgh.2017.04.001.
    1. Miclotte L., Van De Wiele T. Food processing, gut microbiota and the globesity problem. Crit. Rev. Food Sci. Nutr. 2019:1–14. doi: 10.1080/10408398.2019.1596878. in press.
    1. Li G., Xie C., Lu S., Nichols R.G., Tian Y., Li L., Patel D., Ma Y., Brocker C.N., Yan T., et al. Intermittent fasting promotes white adipose browning and decreases obesity by shaping the gut microbiota. Cell Metab. 2017;26:672–685. doi: 10.1016/j.cmet.2017.08.019.
    1. Chevalier C., Stojanovic O., Colin D.J., Suarez-Zamorano N., Tarallo V., Veyrat-Durebex C., Rigo D., Fabbiano S., Stevanovic A., Hagemann S., et al. Gut microbiota orchestrates energy homeostasis during cold. Cell. 2015;163:1360–1374. doi: 10.1016/j.cell.2015.11.004.
    1. Zarrinpar A., Chaix A., Yooseph S., Panda S. Diet and feeding pattern affect the diurnal dynamics of the gut microbiome. Cell Metab. 2014;20:1006–1017. doi: 10.1016/j.cmet.2014.11.008.
    1. Cignarella F., Cantoni C., Ghezzi L., Salter A., Dorsett Y., Chen L., Phillips D., Weinstock G.M., Fontana L., Cross A.H., et al. Intermittent fasting confers protection in CNS autoimmunity by altering the gut microbiota. Cell Metab. 2018;27:1222–1235. doi: 10.1016/j.cmet.2018.05.006.
    1. Rangan P., Choi I., Wei M., Navarrete G., Guen E., Brandhorst S., Enyati N., Pasia G., Maesincee D., Ocon V., et al. Fasting-mimicking diet modulates microbiota and promotes intestinal regeneration to reduce inflammatory bowel disease pathology. Cell Rep. 2019;26:2704–2719. doi: 10.1016/j.celrep.2019.02.019.
    1. Catterson J.H., Khericha M., Dyson M.C., Vincent A.J., Callard R., Haveron S.M., Rajasingam A., Ahmad M., Partridge L. Short-term, intermittent fasting induces long-lasting gut health and TOR-independent lifespan extension. Curr. Biol. 2018;28:1714–1724. doi: 10.1016/j.cub.2018.04.015.
    1. Muccioli G.G., Naslain D., Backhed F., Reigstad C.S., Lambert D.M., Delzenne N.M., Cani P.D. The endocannabinoid system links gut microbiota to adipogenesis. Mol. Syst. Biol. 2010;6:392. doi: 10.1038/msb.2010.46.
    1. Pesce M., Esposito G., Sarnelli G. Endocannabinoids in the treatment of gasytrointestinal inflammation and symptoms. Curr. Opin. Pharmacol. 2018;43:81–86. doi: 10.1016/j.coph.2018.08.009.
    1. De Filippis D., Esposito G., Cirillo C., Cipriano M., De Winter B.Y., Scuderi C., Sarnelli G., Cuomo R., Steardo L., De Man J.G., et al. Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis. PLoS ONE. 2011;6:e28159. doi: 10.1371/journal.pone.0028159.
    1. Uranga J.A., Vera G., Abalo R. Cannabinoid pharmacology and therapy in gut disorders. Biochem. Pharmacol. 2018;157:134–147. doi: 10.1016/j.bcp.2018.07.048.
    1. Le Strat Y., Le Foll B. Obesity and cannabis use: Results from 2 representative national surveys. Am. J. Epidemiol. 2011;174:929–933. doi: 10.1093/aje/kwr200.
    1. Cluny N.L., Keenan C.M., Reimer R.A., Le Foll B., Sharkey K.A. Prevention of diet-induced obesity effects on body weight and gut microbiota in mice treated chronically with delta9-tetrahydrocannabinol. PLoS ONE. 2015;10:e0144270. doi: 10.1371/journal.pone.0144270.
    1. Zhang L., Huang Y., Zhou Y., Buckley T., Wang H.H. Antibiotic administration routes significantly influence the levels of antibiotic resistance in gut microbiota. Antimicrob. Agents Chemother. 2013;57:3659–3666. doi: 10.1128/AAC.00670-13.
    1. O’Donoghue C., Solomon K., Fenelon L., Fitzpatrick F., Kyne L. Effect of proton pump inhibitors and antibiotics on the gut microbiome of hospitalised older persons. J. Infect. 2016;72:498–500. doi: 10.1016/j.jinf.2016.01.015.
    1. Blaser M.J. Antibiotic use and its consequences for the normal microbiome. Science. 2016;352:544–545. doi: 10.1126/science.aad9358.
    1. Su T., Lai S., Lee A., He X., Chen S. Meta-analysis: Proton pump inhibitors moderately increase the risk of small intestinal bacterial overgrowth. J. Gastroenterol. 2018;53:27–36. doi: 10.1007/s00535-017-1371-9.
    1. Trifan A., Stanciu C., Girleanu I., Stoica O.C., Singeap A.M., Maxim R., Chiriac S.A., Ciobica A., Boiculese L. Proton pump inhibitors therapy and risk of Clostridium difficile infection: Systematic review and meta-analysis. World J. Gastroenterol. 2017;23:6500–6515. doi: 10.3748/wjg.v23.i35.6500.
    1. Le Bastard Q., Al-Ghalith G.A., Gregoire M., Chapelet G., Javaudin F., Dailly E., Batard E., Knights D., Montassier E. Systematic review: Human gut dysbiosis induced by non-antibiotic prescription medications. Aliment. Pharmacol. Ther. 2018;47:332–345. doi: 10.1111/apt.14451.
    1. Imhann F., Bonder M.J., Vich Vila A., Fu J., Mujagic Z., Vork L., Tigchelaar E.F., Jankipersadsing S.A., Cenit M.C., Harmsen H.J., et al. Proton pump inhibitors affect the gut microbiome. Gut. 2016;65:740–748. doi: 10.1136/gutjnl-2015-310376.
    1. Bahr S.M., Tyler B.C., Wooldridge N., Butcher B.D., Burns T.L., Teesch L.M., Oltman C.L., Azcarate-Peril M.A., Kirby J.R., Calarge C.A. Use of the second-generation antipsychotic, risperidone, and secondary weight gain are associated with an altered gut microbiota in children. Transl. Psychiatry. 2015;5:e652. doi: 10.1038/tp.2015.135.
    1. Flowers S.A., Evans S.J., Ward K.M., McInnis M.G., Ellingrod V.L. Interaction between atypical antipsychotics and the gut microbiome in a bipolar disease cohort. Pharmacotherapy. 2017;37:261–267. doi: 10.1002/phar.1890.
    1. Rogers M.A.M., Aronoff D.M. The influence of non-steroidal anti-inflammatory drugs on the gut microbiome. Clin. Microbiol. Infect. 2016;22:178. doi: 10.1016/j.cmi.2015.10.003.
    1. Meng J., Yu H., Ma J., Wang J., Banerjee S., Charboneau R., Barke R.A., Roy S. Morphine induces bacterial translocation in mice by compromising intestinal barrier function in a TLR-dependent manner. PLoS ONE. 2013;8:e54040. doi: 10.1371/journal.pone.0054040.
    1. Sharon G., Cruz N.J., Kang D.W., Gandal M.J., Wang B., Kim Y.M., Zink E.M., Casey C.P., Taylor B.C., Lane C.J., et al. Human gut microbiota from autism spectrum disorder promote behavioral symptoms in mice. Cell. 2019;177:1600–1618. doi: 10.1016/j.cell.2019.05.004.
    1. Martinez G.P., Bauerl C., Collado M.C. Understanding gut microbiota in elderly’s health will enable intervention through probiotics. Benef. Microbes. 2014;5:235–246. doi: 10.3920/BM2013.0079.
    1. Davenport E.R., Mizrahi-Man O., Michelini K., Barreiro L.B., Ober C., Gilad Y. Seasonal variation in human gut microbiome composition. PLoS ONE. 2014;9:e90731. doi: 10.1371/journal.pone.0090731.
    1. O’Toole P.W., Jeffery I.B. Gut microbiota and aging. Science. 2015;350:1214–1215. doi: 10.1126/science.aac8469.
    1. Armour C.R., Nayfach S., Pollard K.S., Sharpton T.J. A metagenomic meta-analysis reveals functional signatures of health and disease in the human gut microbiome. mSystems. 2019;4:e00332-18. doi: 10.1128/mSystems.00332-18.
    1. Brunt V.E., Gioscia-Ryan R.A., Richey J.J., Zigler M.C., Cuevas L.M., Gonzalez A., Vazquez-Baeza Y., Battson M.L., Smithson A.T., Gilley A.D., et al. Suppression of the gut microbiome ameliorates age-related arterial dysfunction and oxidative stress in mice. J. Physiol. 2019;597:2361–2378. doi: 10.1113/JP277336.
    1. Smith P., Willemsen D., Popkes M., Metge F., Gandiwa E., Reichard M., Valenzano D.R. Regulation of life span by the gut microbiota in the short-lived African turquoise killifish. eLife. 2017;6:e27014. doi: 10.7554/eLife.27014.
    1. Tirosh A., Calay E.S., Tuncman G., Claiborn K.C., Inouye K.E., Eguchi K., Alcala M., Rathaus M., Hollander K.S., Ron I., et al. The short-chain fatty acid propionate increases glucagon and FABP4 production, impairing insulin action in mice and humans. Sci. Transl. Med. 2019;11:eaav0120. doi: 10.1126/scitranslmed.aav0120.
    1. Perry R.J., Peng L., Barry N.A., Cline G.W., Zhang D., Cardone R.L., Petersen K.F., Kibbey R.G., Goodman A.L., Shulman G.I. Acetate mediates a microbiome-brain-beta-cell axis to promote metabolic syndrome. Nature. 2016;534:213–217. doi: 10.1038/nature18309.
    1. Si X., Shang W., Zhou Z., Strappe P., Wang B., Bird A., Blanchard C. Gut microbiome-induced shift of acetate to butyrate positively manages dysbiosis in high fat diet. Mol. Nutr. Food Res. 2018;62:1700670. doi: 10.1002/mnfr.201700670.
    1. Laforest-Lapointe I., Arrieta M.C. Microbial eukaryotes: A missing link in gut microbiome studies. mSystems. 2018;3:e00201-17. doi: 10.1128/mSystems.00201-17.
    1. Rampelli S., Turroni S., Schnorr S.L., Soverini M., Quercia S., Barone M., Castagnetti A., Biagi E., Gallinella G., Brigidi P., et al. Characterization of the human DNA gut virome across populations with different subsistence strategies and geographical origin. Environ. Microbiol. 2017;19:4728–4735. doi: 10.1111/1462-2920.13938.
    1. Hsu B.B., Gibson T.E., Yeliseyev V., Liu Q., Lyon L., Bry L., Silver P.A., Gerber G.K. Dynamic modulation of the gut microbiota and metabolome by bacteriophages in a mouse model. Cell Host Microbe. 2019;25:803–814. doi: 10.1016/j.chom.2019.05.001.
    1. Norman J.M., Handley S.A., Baldridge M.T., Droit L., Liu C.Y., Keller B.C., Kambal A., Monaco C.L., Zhao G., Fleshner P., et al. Disease-specific alterations in the enteric virome in inflammatory bowel disease. Cell. 2015;160:447–460. doi: 10.1016/j.cell.2015.01.002.
    1. Audebert C., Even G., Cian A. The Blastocystis Investigation Group; Loywick, A.; Merlin, S.; Viscogliosi, E.; Chabe, M. Colonization with the enteric protozoa Blastocystis is associated with increased diversity of human gut bacterial microbiota. Sci. Rep. 2016;6:25255. doi: 10.1038/srep25255.
    1. Poirier P., Wawrzyniak I., Vivares C.P., Delbac F., El Alaoui H. New insights into Blastocystis spp.: A potential link with irritable bowel syndrome. PLoS Pathog. 2012;8:e1002545. doi: 10.1371/journal.ppat.1002545.
    1. Yason J.A., Liang Y.R., Png C.W., Zhang Y., Tan K.S.W. Interactions between a pathogenic Blastocystis subtype and gut microbiota: In vitro and in vivo studies. Microbiome. 2019;7:30. doi: 10.1186/s40168-019-0644-3.
    1. Nieves-Ramirez M.E., Partida-Rodriguez O., Laforest-Lapointe I., Reynolds L.A., Brown E.M., Valdez-Salazar A., Moran-Silva P., Rojas-Velazquez L., Morien E., Parfrey L.W., et al. Asymptomatic intestinal colonization with protist Blastocystis is strongly associated with distinct microbiome ecological patterns. mSystems. 2018;3:e00007-18. doi: 10.1128/mSystems.00007-18.
    1. Gentekaki E., Curtis B.A., Stairs C.W., Klimes V., Elias M., Salas-Leiva D.E., Herman E.K., Eme L., Arias M.C., Henrissat B., et al. Extreme genome diversity in the hyper-prevalent parasitic eukaryote Blastocystis. PLoS Biol. 2017;15:e2003769. doi: 10.1371/journal.pbio.2003769.
    1. Zmora N., Suez J., Elinav E. You are what you eat: Diet, health and the gut microbiota. Nat. Rev. Gastroenterol. Hepatol. 2019;16:35–56. doi: 10.1038/s41575-018-0061-2.
    1. Chen F., Du M., Blumberg J.B., Ho Chui K.K., Ruan M., Rogers G., Shan Z., Zeng L., Zhang F.F. Association among dietary supplement use, nutrient intake, and mortality among U.S. adults: A cohort study. Ann. Intern. Med. 2019;170:604–613. doi: 10.7326/M18-2478.
    1. Fetissov S.O. Role of the gut microbiota in host appetite control: Bacterial growth to animal feeding behaviour. Nat. Rev. Endocrinol. 2017;13:11–25. doi: 10.1038/nrendo.2016.150.
    1. Thorburn A.N., Macia L., Mackay C.R. Diet, metabolites, and “Western-lifestyle” inflammatory diseases. Immunity. 2014;40:833–842. doi: 10.1016/j.immuni.2014.05.014.
    1. Vieira-Silva S., Sabino J., Valles-Colomer M., Falony G., Kathagen G., Caenepeel C., Cleynen I., Van Der Merwe S., Vermeire S., Raes J. Quantitative microbiome profiling disentangles inflammation- and bile duct obstruction-associated microbiota alterations across PSC/IBD diagnoses. Nat. Microbiol. 2019 doi: 10.1038/s41564-019-0483-9. in press.
    1. Hillman E.T., Lu H., Yao T., Nakatsu C.H. Microbial ecology along the gastrointestinal tract. Microbes Environ. 2017;32:300–313. doi: 10.1264/jsme2.ME17017.
    1. Crespo-Piazuelo D., Estelle J., Revilla M., Criado-Mesas L., Ramayo-Caldas Y., Ovilo C., Fernandez A.I., Ballester M., Folch J.M. Characterization of bacterial microbiota compositions along the intestinal tract in pigs and their interactions and functions. Sci. Rep. 2018;8:12727. doi: 10.1038/s41598-018-30932-6.
    1. Johnson A.J., Vangay P., Al-Ghalith G.A., Hillmann B.M., Ward T.L., Shields-Cutler R.R., Kim A.D., Shmagel A.K., Syed A.N., Walter J., et al. Daily sampling reveals personalized diet-microbiome associations in humans. Cell Host Microbe. 2019;25:789–802. doi: 10.1016/j.chom.2019.05.005.
    1. David L.A., Maurice C.F., Carmody R.N., Gootenberg D.B., Button J.E., Wolfe B.E., Ling A.V., Devlin A.S., Varma Y., Fischbach M.A., et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014;505:559–563. doi: 10.1038/nature12820.
    1. Zimmermann M., Zimmermann-Kogadeeva M., Wegmann R., Goodman A.L. Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019;570:462–467. doi: 10.1038/s41586-019-1291-3.
    1. De Toro-Martin J., Arsenault B.J., Despres J.P., Vohl M.C. Precision nutrition: A review of personalized nutritional approaches for the prevention and management of metabolic syndrome. Nutrients. 2017;9:913. doi: 10.3390/nu9080913.
    1. Zhang N., Ju Z., Zuo T. Time for food: The impact of diet on gut microbiota and human health. Nutrition. 2018;51–52:80–85. doi: 10.1016/j.nut.2017.12.005.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit